Serveur d'exploration Tocilizumab - Checkpoint (Pmc)

Index « Auteurs » - entrée « Motomu Hashimoto »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Motoki Sato < Motomu Hashimoto < Motonobu Saito  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 4.
Ident.Authors (with country if any)Title
000227 (2020) Hiroto Minamino [Japon] ; Masao Katsushima [Japon] ; Tamami Yoshida [Japon] ; Motomu Hashimoto [Japon] ; Yoshihito Fujita [Japon] ; Mirei Shirakashi [Japon] ; Wataru Yamamoto [Japon] ; Kosaku Murakami [Japon] ; Koichi Murata [Japon] ; Kohei Nishitani [Japon] ; Masao Tanaka [Japon] ; Hiromu Ito [Japon] ; Nobuya Inagaki [Japon] ; Shuichi Matsuda [Japon]Increased circulating adiponectin is an independent disease activity marker in patients with rheumatoid arthritis: A cross-sectional study using the KURAMA database
000967 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study-
000A15 (2019) Kosuke Ebina [Japon] ; Motomu Hashimoto [Japon] ; Wataru Yamamoto [Japon] ; Toru Hirano [Japon] ; Ryota Hara [Japon] ; Masaki Katayama [Japon] ; Akira Onishi [Japon] ; Koji Nagai [Japon] ; Yonsu Son [Japon] ; Hideki Amuro [Japon] ; Keiichi Yamamoto [Japon] ; Yuichi Maeda [Japon] ; Koichi Murata [Japon] ; Sadao Jinno [Japon] ; Tohru Takeuchi [Japon] ; Makoto Hirao [Japon] ; Atsushi Kumanogoh [Japon] ; Hideki Yoshikawa [Japon]Correction to: Drug tolerability and reasons for discontinuation of seven biologics in 4466 treatment courses of rheumatoid arthritis—the ANSWER cohort study
000E18 (2017) Shuichiro Nakabo ; Motomu Hashimoto ; Shinji Ito ; Moritoshi Furu [Japon] ; Hiromu Ito [Japon] ; Takao Fujii ; Hajime Yoshifuji ; Yoshitaka Imura ; Ran Nakashima ; Kosaku Murakami ; Nobuo Kuramoto ; Masao Tanaka ; Junko Satoh ; Akihito Ishigami [Japon] ; Satoshi Morita [Japon] ; Tsuneyo Mimori ; Koichiro OhmuraCarbamylated albumin is one of the target antigens of anti-carbamylated protein antibodies

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Pmc/Checkpoint
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/Author.i -k "Motomu Hashimoto" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/Author.i  \
                -Sk "Motomu Hashimoto" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Author.i
   |clé=    Motomu Hashimoto
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021